EGFR and non-small cell lung carcinoma: For instance, TNBC patients bearing mutations in PIK3CA, AKT1, and ESR1, as well as EGFR amplifications, may be treated with different drugs to those that are used to treat other subtypes of breast cancer (BRCA) and Non-Small Cell Lung Cancer (NSCLS), respectively.